Efficacy and Safety of First-line MIL60 Plus Paclitaxel/Carboplatin Versus Bevacizumab Plus Paclitaxel/Carboplatin in Patients With Advanced and Recurrent Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Phase 3 Study
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Mabworks Biotech
- 02 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Jun 2020.
- 02 Oct 2019 Planned primary completion date changed from 1 May 2019 to 1 Dec 2019.
- 06 Nov 2017 Status changed from not yet recruiting to recruiting.